Mainz Biomed's ColoFuture Study, Evaluating its Novel mRNA Biomarkers, Reports Groundbreaking Topline Results Demonstrating Sensitivity for Colorectal Cancer of 94% with Specificity of 97% and Advanced Adenoma Sensitivity of 81%
Portfolio Pulse from Benzinga Newsdesk
Mainz Biomed N.V. (NASDAQ:MYNZ) announced positive topline results from its ColoFuture study, a clinical trial assessing the potential to integrate novel gene expression biomarkers into ColoAlert®, a screening test for colorectal cancer. The study reported a sensitivity for colorectal cancer of 94% and a sensitivity for advanced adenoma of 81%.
September 13, 2023 | 7:13 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mainz Biomed's positive topline results from its ColoFuture study could potentially boost the company's stock in the short term.
The positive results from the ColoFuture study indicate the potential for Mainz Biomed's ColoAlert® to be a highly effective screening test for colorectal cancer. This could increase the demand for the product, leading to potential revenue growth and a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100